Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 PYPD | Healthcare | $6.26 | 193.16K | $134.06M | -4.32 | ― | Strong Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| PYPD | PolyPid | 6.26 | 2.75 | 78.27% |
| Name | Price | % Change | |
|---|---|---|---|
| PYPD | $6.26 | +78.27% |
An update from PolyPid ( ($PYPD) ) is now available. PolyPid, an innovative biopharmaceutical company focused on improving patient outcomes, reported on November 11, 2026, that the FDA was conducting
Roth Capital analyst Boobalan Pachaiyappan raised the firm’s price target on PolyPid (PYPD) to $8.50 from $8 and keeps a Buy rating on the shares. Ongoing FDA labeling discussions and
PolyPid Ltd. (($PYPD)) has held its Q3 earnings call. Read on for the main highlights of the call. PolyPid’s earnings call carried a largely positive tone as the company approached
“With our PDUFA goal date fast approaching, this is a defining moment for PolyPid (PYPD),” said Dikla Czaczkes Akselbrad, CEO of PolyPid. “We have a committed partner in Azurity preparing
WSW, NY, November 10th, 2026, FinanceWire With its November 28 FDA target date approaching, PolyPid is preparing for a potential launch while pursuing European partnerships and advancing diabetic foot infection
PolyPid Ltd. (PYPD) is scheduled to report 3rd quarter earnings on 11/11/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect PolyPid Ltd. to post earnings of $0.91
H.C. Wainwright analyst Brandon Folkes maintained a Buy rating on PolyPid today and set a price target of $13.00. Brandon Folkes has given his Buy rating due to a combination
PolyPid ( ($PYPD) ) has provided an announcement. On October 28, 2026, PolyPid announced an expanded pipeline strategy that extends its Kynatrix delivery technology from infection prevention to infection treatment,
As previously reported, Oppenheimer initiated coverage of PolyPid (PYPD) with an Outperform rating and $10 price target The stock in morning trading is up 3% to $5.46. The firm says
Virtual Meeting to be held on October 21 hosted by Craig-Hallum. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| PYPD | Feb 10, 2027TBA | $134.06M | $-0.13 | $6.04M | 0.04 | -4.32 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
